Gelonghui November 7th 丨Some investors asked Kangchen Pharmaceutical (603590.SH) on the investor interactive platform, “Does your company have R&D drugs for diseases such as mammary glands, dermatitis, joints, epilepsy, tumors, cancer, genetic mitochondria, etc., as well as health care products such as weight loss drugs and fitness equipment, please give examples”

The company said that the company focuses on innovative drugs, adheres to clinical value as the guide, is based on innovative drug research and development to fill unmet clinical needs, gives full play to the company's dominant position in the fields of hemostasis, perioperative period, bone metabolism, oncology and immunity, focuses on promoting innovative drug research and development, and enhancing the company's sustainable development capabilities. The company's main products sold by the company are “Surin” and “Meganite”. “Sulin” is the only national first-class hemagglutinase preparation in China. Since its launch, it has helped tens of millions of patients to stop bleeding with surgery, and has high pharmacoeconomic value. “Close Coverage” is the only calcitonin product with indications to stop acute and progressive bone loss. It has been recommended by many authoritative guidelines at home and abroad, and has a stable market base and profitability in the field of osteoporosis and acute bone loss.

At the same time, the drugs being developed by the company have gradually formed a competitive product pipeline, mainly including KC1036, golden herb tablets, and viper hemagglutinin for dogs, etc., which have strongly supported the new situation of the company's innovative drug research and development. KC1036 is a multi-target receptor tyrosine kinase inhibitor such as AXL, VEGFR, CSF-1R, and FLT3 independently developed by the company. Phase II clinical research is currently being carried out in an orderly manner. KC1036 has included more than 100 advanced solid tumor subjects in multiple clinical trials, and significant clinical efficacy has been observed in various solid tumors such as esophageal cancer and thymic carcinoma. Jincao tablets are the only innovative product approved by the State Drug Administration for effective parts of traditional Chinese medicine for “chronic pelvic pain, a sequelae of pelvic inflammatory disease”. They have the characteristics of controllable quality, good safety, and clinical evaluation standards in line with international standards. According to the results of the phase II clinical trial, goldenrod tablets can significantly improve the symptoms of lower abdominal pain, have a long-lasting effect, and can significantly improve the quality of life of patients. Currently, the phase III clinical trial of Jincao tablets is progressing smoothly, and the enrollment of all subjects has been completed.

The entry of viper hemagglutinin into the field of pet medicine is a major step in the life cycle management of “Surin”. Once successfully marketed, this product will bring new hemostasis options to pet surgery. Currently, the application for registration of a new drug for injectable viper hemagglutinin in dogs has been accepted.